Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Each of MEDVis GLP-1 formats comes with unique advantages, and the best choice depends on your lifestyle, comfort level, and health profile
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial, Lancet (2026) [PubMed abstract] Tirzepatide (Zepbound) review
Those who stayed on treatment lost an average of 11.7% of their body weight
Patients should be counseled to report severe abdominal pain (potential pancreatitis), right upper quadrant pain (possible gallbladder disease), visual changes (especially with diabetic retinopathy), persistent nausea or vomiting, or signs of dehydration which may increase risk of acute kidney injury
Our results outperform the expected percentage from the trials and are usually achieved by those who adopt lifestyle modifications which promote a healthful lifestyle as well as individual responsiveness to the medication
Many of our patients tell us theyve tried everything from targeted workouts to special diets, only to find their thigh contours resistant to change
